5 Pharmaceutical Price Target Raises From Jefferies
Jefferies' Jeffrey Holford raised five pharmaceuticals following key news on each company's products:
- Abbott (NYSE: ABT) increased the price target to $45.00 after Abbot reported positive results from Type-1 Diabetes study. The study showed that Abbott system's significantly reduced Hypoglycemia.
- Bristol-Myers Squibb Company (NYSE: BMY) raised the price objective to $78.00 after the company announced new data demonstrating continued research expansion and Immuno-Oncology Advancements across multiple blood cancers. Additionally, Bristo-Myers Squibb announced new data on Opdivo which indicated benefit in heavily pre-treated classical Hodgkin Lymphoma Patients in Phase 2.
- Johnson and Johnson (NYSE: JNJ) price target raised to $109.00 after it announced EPREX demonstrated effectiveness as treatment for Anaemia in patients with low or intermediate-1 risk of Myelodysplastic syndromes at EHA Saturday.
- Pfizer (NYSE: PFE)'s price target rose to $42.00 after the company announced two pivotal phase 3 studies for Ertuglifozin Met Primary Endpoints, showing significant A1C reductions in patients with Type 2 Diabetes at the American Diabetes Association's 76th scientific sessions Sunday.
- Zoetis (NYSE: ZTS) increased the price objective to $58.00 after Zoetis shares rose considerably over the last three months.
Latest Ratings for ABT
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.